BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

...4.6 million shares at $87. Mental health diagnostic play Psyomics closes £1.5M roundUniversity of Cambridge spinout Psyomics...
...Toll-like receptor 7 Paul Bonanos Apellis Pharmaceuticals Inc. Swedish Orphan Biovitrum AB Primmune Therapeutics Inc. Prokarium Ltd. RegenxBio Inc. Turning Point Therapeutics Inc. Psyomics...
Items per page:
1 - 1 of 1
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

...4.6 million shares at $87. Mental health diagnostic play Psyomics closes £1.5M roundUniversity of Cambridge spinout Psyomics...
...Toll-like receptor 7 Paul Bonanos Apellis Pharmaceuticals Inc. Swedish Orphan Biovitrum AB Primmune Therapeutics Inc. Prokarium Ltd. RegenxBio Inc. Turning Point Therapeutics Inc. Psyomics...
Items per page:
1 - 1 of 1